
Top 10 stories of 2020
It’s another Optometry Times® holiday tradition: the end-of-year top stories list.
Let’s take a look back at that unprecedented year that just ended…and what stories our readers found interesting and worthy of their time.
YOU, dear reader, decide which stories make this list.
We calculate which stories received the most clicks on our website. Those website visits are also driven by our email newsletters and social media postings. Clicking on a story adds a vote for that story.
In an interesting twist, all stories in the top 10 are new to the list. That tells us that readers found our new content compelling.
A common thread in our top 10 stories, of course, is
Before diving into 2020’s top stories, see the top stories for the past few years.
Here are 2020’s top stories of the year.
10.
Associate Editor
This article summarizes new data from Tarsus Pharmaceuticals on its
The Phase 2b Mars study “demonstrated that the use of TP-03 for 4 weeks was well-tolerated and showed promising efficacy in the treatment of demodex blepharitis with treatment effects persisting for at least 90 days, according to the company,” Brooke writes.
Find out the study details
9.
She writes: “Throughout the quarantine, I have noticed an interesting shift in ocular problems at my practice. Some of the common ocular ‘emergencies’ have presented more frequently over the past several months, including
8.
He writes: “The participants who purchased their
The study also looked at hygiene and risk factors for patients who purchase contact lenses online.
7.
This piece from
Dr. Casella reviewed a case control study on risk factors for contact lens-related microbial keratitis.
He writes: “The results were intriguing. When compared to never showering with contact lenses, those who showered with them in every day had over 7 times the risk of developing a corneal infection.”
Read the full article
6.
Here is another entry of COVID-19 stories, and associate editor
In late October 2020, remdesivir (Veklury) from Gilead Science became the U.S.’s first Food & Drug Administration (FDA)-approved drug for treating the coronavirus.
She also outlined other treatments for COVID-19 in the pipeline.
5.
Associate Editor
See the update
4.
Editor Emeritus
And judging its Number 4 spot in the list, ODs appreciated his timely reasearch.
Dr. Bowling offered a timeline of the pandemic, transmission details, ocular manifestations, and precautions to take.
Read his story
3.
Hitting the list in the Number 3 spot,
This article also appeared early in the pandemic, and it outlined what ODs need to know about this drug.
Read her update
2.
This story harkens from December 2019. Given its Number 2 position in this year’s list, its topic readers clearly resonated during the pandemic.
Check out why
1.
Hitting our Number 1 spot—by a huge margin—Associate Editor
She writes: “Findings from an observational study of more than 100 patients show headache onset may occur during the presymptomatic and/or symptomatic phases of COVID-19 progression and sometimes mimics tension or migraine headaches.”
See our top story of 2020
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.


















































.png)


